The increasing role of primary care physicians in caring for patients with type 2 diabetes mellitus

Mayo Clinic Proceedings

Volumn 85, Issue 12 SUPPL., 2010, Pages

  Davidson, Jaime A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INCRETIN;

CARDIOVASCULAR RISK; EDITORIAL; HEALTH CARE PERSONNEL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PHYSICIAN; PREVALENCE; PRIMARY MEDICAL CARE;

EID: 78650114731     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0466     Document Type: Editorial

References (10)

1. International Diabetes Federation Atlas 2009. Diabetes and impaired glucose tolerance: global burden: prevalence and projections, 2010 and 2030. International Diabetes Federation Web site. http://www.diabetesatlas.org/ content/diabetes-and-impaired-glucose-tolerance. Accessed September 16, 2010.
2. National Diabetes Information Clearinghouse (NDIC). National diabetes statistics, 2007. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Last update: June 2008. Accessed September 16, 2010.
3. Eeg-Olofsson K, Cederholm J, Nilsson PM, et al. Risk of cardiovascular disease and mortality in overweight and obese patients with type 2 diabetes: an observational study in 13,087 patients. Diabetologia. 2009;52(1):65-73.
4. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009;120(3):212-220.
5. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122:443-453.
6. Freeman JS. A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12)(suppl):S5-S14.
7. Schwartz SS, Kohl BA. Glycemic control and weight reduction without causing hypoglycemia: the case for continued safe aggressive care of patients with type 2 diabetes mellitus and avoidance of therapeutic inertia. Mayo Clin Proc. 2010;85(12)(suppl):S15-S26.
8. Davidson JA: Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc. 2010;85(12)(suppl):S27-S37.
9. Unger J. Incretins: clinical perspectives, relevance, and applications for the primary care physician in the treatment of patients with type 2 diabetes. Mayo Clin Proc. 2010;85(12)(suppl):S38-S49.
10. Stolar MW. Defining and achieving treatment success in patients with type 2 diabetes mellitus. Mayo Clin Proc. 2010;85(12)(suppl):S50-S59.